Powered by OpenAIRE graph
Found an issue? Give us feedback

INS

Instituto Nacional de Saúde
12 Projects, page 1 of 3
  • Funder: European Commission Project Code: 101145636
    Overall Budget: 4,370,390 EURFunder Contribution: 4,370,390 EUR

    The SOuthern aFrica Research cApacity netwoRk (SOFAR) will train a generation of innovative world class and resilient African scientists, clinicians and public health professionals facilitated by a partnership of two higher education institutions (HEIs) in Europe and three African Partner Research Institutions (APRIs) with proven track records of research excellence. SOFAR will train 4 MSc, 6 PhD fellows in high quality and relevant infectious disease research combining taught content with practical experience, and support 5 post-doctoral researchers in conducting high quality infectious disease research on a pathway to establish themselves as independent researchers thus contributing to the generation of a critical mass of research capacity. Training will be delivered through fostering a mutually beneficial network that includes the SOFAR partners ministries of health and policy making organisations, with network meetings, pairing of fellows across institutions and placements of fellows within Africa CDC and WHO. This will facilitate direct transferability of relevant research to practice and policy. SOFAR will develop and deliver a modular digital and face to face training programme (Digital Global Health Academy) aimed at equipping fellows to maximize their research impact. This open access platform will foster a culture of open science, innovation, and knowledge circulation. SOFAR will strengthen processes and systems for recruitment ensuring both transparency and equity through the development of written guidance documents, training and intentional recruitment and review panels; in addition a tailored participatory programme to train academic supervisors at APRIs will be delivered. This will ensure that SOFAR not only trains skilled and internationally competitive researchers, but strengthens the systems and the environment of institutions, ensuring both impact and sustainability and contributing to reversing the brain drain.

    more_vert
  • Funder: European Commission Project Code: 101103171
    Overall Budget: 4,999,170 EURFunder Contribution: 4,999,170 EUR

    The overall goal of GenPath Africa is to control pathogen infections in Africa. Our consortium of African and European investigators proposes to build on our collective experience in responding to SARS-CoV-2 to better diagnose, monitor and clinically manage current and future epidemics in Africa. We propose to expand genomics capacity to combat drug resistant HIV-1 and TB through precision medicine and by using genomic epidemiology to guide the public health response. GenPath Africa will also apply recent developments in wastewater and one health surveillance to detect emerging pathogens. Capacity development activities will include degree training in South Africa and the transfer of technology to the National Public Health Institute of Mozambique. The consortium’s objectives will be achieved by connecting the specialized genomics facilities of the Africa CDC Pathogen Genomics Initiative (Africa PGI) in South Africa and Kenya with African national public health institutes to translate scientific advances into public health actions. Long-term collaborations with Germany and Belgium will be leveraged to help achieve these objectives and make precision medicine and precision public health a reality in southern and East Africa. The consortium will also contribute to the long-term capacity building objectives of Africa PGI by contributing to harmonising training resources and collaboration with existing networks to ensure that all data are of high quality and available in public databases. GenPath Africa will advance the EDTCP3 work program by: i) providing researchers and public health professionals with skills in genomic epidemiology to better understand infectious disease epidemiology and drug resistance, ii) strengthening capability in southern and East Africa to rapidly respond to current and emerging epidemics, and iii) providing researchers with training to advance their scientific careers in Africa and establish themselves as scientific and public health leaders.

    more_vert
  • Funder: European Commission Project Code: 101190925
    Overall Budget: 5,164,860 EURFunder Contribution: 5,164,860 EUR

    The integrase inhibitors dolutegravir (DTG) is recommended by the World Health Organization (WHO) for 1st line antiretroviral therapy (ART) in people living with HIV (PLHIV) since 2018. Despite its high virologic efficacy, there is growing evidence showing massive weight gain and high incidence of metabolic disorders (obesity, type 2 diabetes) and hypertension under DTG, notably among women from sub-Saharan Africa (SSA) women, along with mental health and quality of life issues. The non-nucleoside reverse transcriptase inhibitor doravirine (DOR) is a potent novel ART, recommended in European and North-American guidelines, but not used so far in Southern countries despite interesting virological, safety and resistance profiles. In this context, the ELDORADO project will generate high-quality data on DTG-based ART toxicity and evaluate DOR as an alternative for 1st-line HIV-1 treatment in order to support national and international policymakers in updating national and international guidelines and practices aimed to improve patient outcomes and reduce disease burden of HIV in sub-Saharan Africa and worldwide. The project includes i) a randomized clinical trial assessing the non-inferiority of DOR-based ART as compared to DTG-based ART in terms of virologic efficacy, and its superiority in terms of key safety endpoints (obesity, diabetes, hypertension) in 610 PLHIV from diverse ethnic backgrounds across in SSA (Cameroon, Côte d’Ivoire, Mozambique), Brazil, Thailand, and France, ii) innovative assessments of organ lesions, iii) assessments of mental health and quality of life, iv) health impact and economics modelling based on the trial results as well as that of other trials (NAMSAL) and cohorts (IeDEA West Africa and Brazil). The project will also prioritize capacity building for junior investigators and community advisory board. The ELDORADO trial will be confounded in non-SSA countries by the ANRS|MIE (trial sponsor) and MSD, and benefits from support from the WHO.

    more_vert
  • Funder: European Commission Project Code: 101190730
    Overall Budget: 6,153,640 EURFunder Contribution: 6,113,860 EUR

    Determining how climate and global change are driving the geographical variation of vector-borne diseases (VBDs) transmission dynamics is essential to measure current and future risks and to effectively roll out innovative surveillance and vector control strategies aiming at reducing the burden for the most vulnerable populations, especially in Sub-Saharan Africa (SSA). IMPACTING aims to: 1) model the risk of VBDs spread under global change focusing on mosquitoes (malaria, dengue, chikungunya, yellow fever), tsetse (human African trypanosomiasis), blackflies (onchocerciasis) and ticks (Crimean-Congo haemorrhagic fever); 2) develop vector monitoring and pathogen diagnostic tools for improved surveillance; 3) develop robust pipelines to identify transmission blocking micro-organisms within vectors and define innovative VBD control strategies; 4) engage local rural and urban communities to co-develop solutions for VBD monitoring and control, bypassing current community level barriers; 5) develop a multi-VBD risk prediction dashboard to facilitate evidence-based policy making focused on innovative control strategies resilient to climate change. IMPACTING is built on a consortium of eight research institutes, three universities and one SME - based in Kenya, Cameroon, Mozambique, France and Portugal. It gathers expertise in social sciences, entomology, ecology, epidemiology, genomics, bioinformatics, modelling and software development, fostering an interdisciplinary approach. IMPACTING draws on extensive experience in other EU projects and strong fruitful collaborations to fill the gap in knowledge and innovation for VBDs and vector control in SSA and globally. IMPACTING aligns with the Africa CDC Strategic Plan 2023-27 and EU global health strategy. It focuses on improving health security through African leadership in research and innovation, combining digital and biological sciences, capacity building, and engagement with African communities and public health actors.

    more_vert
  • Funder: European Commission Project Code: 847465
    Overall Budget: 9,969,010 EURFunder Contribution: 9,969,010 EUR

    Tuberculosis is a leading cause of morbidity and mortality worldwide. Current TB treatments are inadequate, requiring patients closely adhere to multi-drug regimens that are long, complex, and often poorly tolerated. These concerns are greatly magnified in rifampicin-resistant (RIF-R) TB, an urgent global and EU public health priority. WHO estimates that only 54% of patients who began RIF-R TB treatment in 2016 were cured. In addition to these well-recognized shortcomings, current TB treatments, particularly those for RIF-R TB, leave a majority of cured patients with permanent, clinically significant lung impairment and radiographic evidence of bronchiectasis and fibrosis. This project will determine if two adjunctive host-directed therapies (HDTs) can prevent these poor outcomes. 330 patients with RIF-R TB and baseline risk factors for poor outcome will be enrolled in a randomized, controlled, 3-armed multi-centre trial, with clinical sites in Romania, Moldova, Georgia, Mozambique, and South Africa. All patients will receive standard multidrug therapy according to national guidelines. Those patients randomized to the experimental arms will in addition receive either CC-11050 or metformin. These selected HDT candidates represent 2 complementary HDT strategies: reducing inflammation vs inducing host cell anti-microbial activity, respectively. Both candidates are supported by data from preclinical and clinical studies. Co-primary efficacy endpoints will examine effects on lung function (measured by spirometry) and infection (measured as time to stable sputum culture conversion). A sub-study will examine quantitative change in lung radiodensity by CT scan. If successful, this ground-breaking project will increase Europe’s capacity to control RIF-R-TB by developing new treatments that increase the likelihood of cure and reduce the risk of life-long disability.

    more_vert
  • chevron_left
  • 1
  • 2
  • 3
  • chevron_right

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected
arrow_drop_down

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.